SSA
KNSA icon

Schonfeld Strategic Advisors’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Schonfeld Strategic Advisors’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-43,599
Closed -$2.1M – 2807
2026
Q1 		$2.1M Sell
43,599
-20,396
-32% -$904K 0.01% 801
2025
Q4 		$2.64M Sell
63,995
-19,886
-24% -$798K 0.01% 777
2025
Q3 		$3.26M Buy
83,881
+15,130
+22% +$492K 0.02% 797
2025
Q2 		$1.9M Buy
68,751
+18,904
+38% +$481K 0.01% 1011
2025
Q1 		$1.11M Buy
49,847
+21,447
+76% +$441K 0.01% 1241
2024
Q4 		$562K Sell
28,400
-60,900
-68% -$1.39M ﹤0.01% 1343
2024
Q3 		$2.23M Buy
89,300
+909
+1% +$22.1K 0.01% 834
2024
Q2 		$1.65M Sell
88,391
-128,517
-59% -$2.41M 0.01% 991
2024
Q1 		$4.28M Sell
216,908
-9,543
-4% -$186K 0.03% 705
2023
Q4 		$3.97M Buy
226,451
+17,951
+9% +$295K 0.03% 577
2023
Q3 		$3.62M Buy
208,500
+134,070
+180% +$2.26M 0.03% 642
2023
Q2 		$1.05M Buy
74,430
+9,432
+15% +$126K 0.01% 951
2023
Q1 		$699K Buy
64,998
+14,998
+30% +$198K 0.01% 1065
2022
Q4 		$749K Buy
+50,000
New +$728K 0.01% 1309
2020
Q3 		– Sell
-15,900
Closed -$405K – 1514
2020
Q2 		$405K Buy
+15,900
New +$332K 0.01% 882
2020
Q1 		– Sell
-38,900
Closed -$430K – 1338
2019
Q4 		$430K Buy
+38,900
New +$338K 0.01% 813

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Schonfeld Strategic Advisors's KNSA Position: Q2 2026 in Review

Schonfeld Strategic Advisors sold out of Kiniksa Pharmaceuticals (KNSA) in Q2 2026, closing a stake of 43,599 shares — an estimated $2.1M sold.

Schonfeld Strategic Advisors first reported a position in KNSA in Q4 2019 and held it in 16 quarters. The position peaked at $4.28M in Q1 2024. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Schonfeld Strategic Advisors reported no remaining Kiniksa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 43,599 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $2.1M.
  • Schonfeld Strategic Advisors first reported a position in Kiniksa Pharmaceuticals in Q4 2019 and held it in 16 quarters.
  • Schonfeld Strategic Advisors's Kiniksa Pharmaceuticals position peaked at $4.28M in Q1 2024.
  • 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.